BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 570
- Registration Number
- NCT05625399
- Locations
- ๐ช๐ธ
Local Institution - 0086, A Coruna, Spain
๐ช๐ธLocal Institution - 0134, Badalona, Spain
๐ช๐ธLocal Institution - 0047, Barcelona, Spain
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: Placebo
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 490
- Registration Number
- NCT05620407
- Locations
- ๐ต๐ช
Local Institution - 0100, Lima, Peru
๐บ๐ธUCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California, United States
๐บ๐ธEast Bay Rheumatology Medical Group, Inc, San Leandro, California, United States
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: Placebo
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 490
- Registration Number
- NCT05617677
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธLocal Institution - 0229, Phoenix, Arizona, United States
๐บ๐ธLocal Institution - 0230, Phoenix, Arizona, United States
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Neoplasms, Ovarian
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 90
- Registration Number
- NCT05613088
- Locations
- ๐บ๐ธ
Local Institution - 0065, Sacramento, California, United States
๐บ๐ธLocal Institution - 0025, San Francisco, California, United States
๐บ๐ธLocal Institution - 0061, Columbus, Ohio, United States
A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Dietary Supplement: Glucose
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT05615012
- Locations
- ๐บ๐ธ
Local Institution - 0001, Miami, Florida, United States
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9000
- Registration Number
- NCT05605782
- Locations
- ๐บ๐ธ
Evidera, Bethesda, Maryland, United States
A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT05599685
- Locations
- ๐ฌ๐ท
Local Institution - 0001, Athens, Greece
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- Other: Placebo
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 580
- Registration Number
- NCT05582395
- Locations
- ๐บ๐ธ
Local Institution - 0082, Birmingham, Alabama, United States
๐บ๐ธLocal Institution - 0458, Phoenix, Arizona, United States
๐บ๐ธLocal Institution - 0409, La Jolla, California, United States
A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT05579574
- Locations
- ๐บ๐ธ
Local Institution - 0001, Anaheim, California, United States
๐บ๐ธLocal Institution - 0002, Anaheim, California, United States
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT05577715
- Locations
- ๐บ๐ธ
Rocky Mountain Cancer Centers - Lone Tree, Lone Tree, Colorado, United States
๐บ๐ธClermont Oncology Center, Clermont, Florida, United States
๐บ๐ธMid Florida Cancer Center - Orange City, Orange City, Florida, United States